HPIV Nucleic Acid Detection Using Position-Specific Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid-based detection techniques for Human Parainfluenza Viruses (HPIVs) face challenges due to sequence heterogeneity, leading to sensitivity and specificity issues in detecting and quantifying HPIVs, particularly HPIV-3, which complicates timely diagnosis and appropriate treatment.
Innovation Solution
The use of specific first and second amplification oligomers targeting defined positions in the HPIV-3 genome, such as positions 1295-1305, 1350-1360, and 1380-1390, or hybridizing to positions 1270 and 1355, 1437, to produce an HPIV-3 amplicon of at least 50 nucleotides, along with optional third and fourth oligomers for detection, enhances sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If nucleic acid-based detection techniques are used for HPIV detection, then rapid detection and quantification is achieved, but sensitivity and specificity are compromised due to sequence heterogeneity
Solution Approach 1:
The patent divides the HPIV detection into multiple targeted regions across different viral genomes (HPIV-1, HPIV-2, HPIV-3, HPIV-4), each with specific primer pairs designed to amplify distinct genomic segments. This segmentation allows each detection reaction to focus on a specific viral type, improving specificity while maintaining rapid detection capability through parallel processing of multiple samples.
Solution Approach 2:
The patent employs location-specific primer pairs targeting unique genomic regions of each HPIV type. For example, HPIV-1 primers target positions 330-490 or 960-1100, while HPIV-3 primers target positions 1295-1305, 1350-1360, or 1380-1390. This local quality approach ensures that each detection reaction is optimized for its specific viral target, enhancing both sensitivity and specificity by eliminating cross-reactivity between different HPIV types.
2Measurement precision
If amplification oligomers target specific positions in HPIV-3 genome, then sensitivity and specificity are improved, but detection complexity increases
Solution Approach 1:
The patent provides a universal detection system that can simultaneously detect all four HPIV types using a single reaction mixture containing multiple primer pairs and probes. This multi-functional approach allows one detection system to handle diverse viral targets, improving sensitivity and specificity for each type while actually reducing overall complexity compared to separate detection systems for each virus type.
Solution Approach 2:
The patent introduces a dimensional approach by using fluorescently labeled probes that emit signals at different wavelengths or fluorescence intensities corresponding to different HPIV types. This allows the detection system to distinguish between viral types not just through separate reactions but through spectral dimensions, simplifying the overall detection architecture while maintaining high specificity for each viral type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for sensitive and specific detection and quantification of HPIV-3, improving diagnostic accuracy and enabling timely treatment by reducing false positives and negatives.
Implementation Method 1
the first amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1270 and the second amplification oligomer is configured to hybridize to a site comprising HPIV-3 position 1355
Implementation Method 2
performing a nucleic acid amplification reaction in the composition which produces an HPIV-3 amplicon of at least about 50 nucleotides in length
Data Source
AI summary
Compositions, methods, kits, and uses are provided for detecting or quantifying an Human Parainfluenza virus 1 (HPIV-1), HPIV-2, HPIV-3, and/or HPIV-4 nucleic acid, e.g., using nucleic acid amplification and hybridization assays. In some embodiments, the compositions, methods, kits, and uses target the HN gene of HPIV-1, HPIV-2, and/or HPIV-3 and/or the NP gene of HPIV-4.